Oncolytics Biotech Inc. Files Routine 6-K Report
Ticker: ONCY · Form: 6-K · Filed: Aug 28, 2025 · CIK: 1129928
| Field | Detail |
|---|---|
| Company | Oncolytics Biotech INC (ONCY) |
| Form Type | 6-K |
| Filed Date | Aug 28, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, sec-filing, foreign-private-issuer
Related Tickers: ONCO
TL;DR
ONCO files routine 6-K, no major news, just standard reporting.
AI Summary
Oncolytics Biotech Inc. filed a Form 6-K on August 28, 2025, reporting as a foreign private issuer. The company, based in Calgary, Alberta, Canada, is subject to the 1934 Securities Exchange Act and will file its annual reports under Form 20-F. This filing does not appear to contain specific financial transactions or material updates beyond its routine reporting status.
Why It Matters
This filing indicates Oncolytics Biotech Inc. is fulfilling its regular reporting obligations as a foreign private issuer, which is standard for companies listed on US exchanges but based internationally.
Risk Assessment
Risk Level: low — This is a routine filing by a foreign private issuer and does not contain new material information or financial events.
Key Players & Entities
- ONCOLYTICS BIOTECH INC (company) — Filer of the report
- August 2025 (date) — Reporting period for the Form 6-K
- 20250828 (date) — Filing date of the report
- Calgary, Alberta, Canada (location) — Principal executive offices of the company
- Form 20-F (document) — Annual report form the company will file
- Form 6-K (document) — Type of report being filed
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is for Oncolytics Biotech Inc. to report as a foreign private issuer for the month of August 2025, fulfilling its ongoing disclosure requirements.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed with the SEC on August 28, 2025.
Where are Oncolytics Biotech Inc.'s principal executive offices located?
Oncolytics Biotech Inc.'s principal executive offices are located at Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5.
Under which act is this report filed?
This report is filed under the 1934 Securities Exchange Act.
Does Oncolytics Biotech Inc. file annual reports under Form 20-F or Form 40-F?
Oncolytics Biotech Inc. indicates it files annual reports under cover of Form 20-F.
Filing Stats: 334 words · 1 min read · ~1 pages · Grade level 17.1 · Accepted 2025-08-28 08:34:50
Filing Documents
- form6ksep2025confs.htm (6-K) — 17KB
- sep2025confs.htm (EX-99.1) — 13KB
- 0001129928-25-000070.txt ( ) — 31KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date August 28, 2025 Kirk Look Chief Financial Officer